Omnia Biologics

Rockville, United States Founded: 2001 • Age: 25 yrs Acquired By Vigene Biosciences
Process development and manufacturing services for biologics are provided.
Request Access

About Omnia Biologics

Omnia Biologics is a company based in Rockville (United States) founded in 2001 was acquired by Vigene Biosciences in November 2016.. Omnia Biologics has raised $25.4 million across 2 funding rounds from investors including Vigene Biosciences and Medipost. Omnia Biologics offers products and services including Process Development, Analytical Development, GMP Manufacturing, and Commercial Manufacturing. Omnia Biologics operates in a competitive market with competitors including KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others.

  • Headquarter Rockville, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Omniabio Inc
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $25.4 M (USD)

    in 2 rounds

  • Latest Funding Round
    $23.9 M (USD), Series B

    May 24, 2022

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Vigene Biosciences

    (Nov 29, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Omnia Biologics

Omnia Biologics offers a comprehensive portfolio of products and services, including Process Development, Analytical Development, GMP Manufacturing, and Commercial Manufacturing. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Optimizes processes for cell and gene therapy production.

Develops assays for quality control in therapies.

Delivers compliant manufacturing for cell therapies.

Supports large-scale therapy production and delivery.

People of Omnia Biologics
Headcount 50-200
Employee Profiles 22
Employee Profiles
People
Tony Rotunno
Site Head
People
Sabrina Sam
Quality Assurance Associate
People
Zahra Sheikholeslami
Associate Director
People
Jennifer Patterson
Senior Manager Quality Control

Unlock access to complete

Funding Insights of Omnia Biologics

Omnia Biologics has successfully raised a total of $25.4M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $23.9 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $23.9M
  • First Round

    (22 May 2006)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2022 Amount Series B - Omnia Biologics Valuation Medipost
May, 2006 Amount Seed - Omnia Biologics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Omnia Biologics

Omnia Biologics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Vigene Biosciences and Medipost. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Research reagents for drug discovery and functional genomics are developed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Omnia Biologics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Omnia Biologics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Omnia Biologics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Omnia Biologics

Omnia Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of protein formulation, process & cell line development, and cGMP services
domain founded_year HQ Location
Biologics development and manufacturing services are offered by EirGenix.
domain founded_year HQ Location
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
domain founded_year HQ Location
Developer of therapeutics for microbiome based diseases
domain founded_year HQ Location
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services
domain founded_year HQ Location
Vaccines and biologics are developed and manufactured by IDT Biologika.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Omnia Biologics

When was Omnia Biologics founded?

Omnia Biologics was founded in 2001 and raised its 1st funding round 5 years after it was founded.

Where is Omnia Biologics located?

Omnia Biologics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.

Is Omnia Biologics a funded company?

Omnia Biologics is a funded company, having raised a total of $25.4M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on May 22, 2006.

What does Omnia Biologics do?

Omnia Biologics was founded in 2001 in Rockville, United States, focusing on the biologics sector. Non-GMP and GMP facilities were utilized for process development from preclinical stages through Phase III manufacturing. Expertise encompassed adenovirus, lentivirus, retrovirus, AAV, VLP, and other viral platforms. Services included manufacturing, process development, cell and virus banking, and aseptic filling. Orders are no longer accepted, with diversions directed to Vigene Biosciences.

Who are the top competitors of Omnia Biologics?

Omnia Biologics's top competitors include KBI Biopharma, Aldevron and Ovagen.

What products or services does Omnia Biologics offer?

Omnia Biologics offers Process Development, Analytical Development, GMP Manufacturing, and Commercial Manufacturing.

Who are Omnia Biologics's investors?

Omnia Biologics has 2 investors. Key investors include Vigene Biosciences, and Medipost.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available